Miura T, Murai T, Shimura H, Kondo I
Department of Urology, Kanagawa Cancer Center.
Hinyokika Kiyo. 1993 Mar;39(3):209-12.
We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy. Recombinant human G-CSF was administered at 2 micrograms/kg subcutaneously starting after the white blood cell count was less than 3,000/mm3 (short administration) or starting immediately after finishing MEC therapy (prophylactic administration). The median white blood cell nadir for the control group, short administration group and prophylactic administration group, was 275 +/- 77, 250 +/- 317 and 2,066 +/- 47/mm3, respectively. The number of days with a white blood count of less than 1,000/mm3 for the control group, short administration group and prophylactic administration group was 6.6 +/- 0.6, 4 +/- 2 and 0.9 +/- 0.5 days, respectively. The difference between the control group and prophylactic administration group was statistically significant (p < 0.01). These findings indicated that the prophylactic administration of rhG-CSF following MEC therapy was effective for preventing leukopenia. Other side effects of stomatitis, diarrhea and pneumonia were also decreased using rhG-CSF after MEC therapy.
我们确定了重组人粒细胞集落刺激因子（rhG-CSF）在接受甲氨蝶呤、依托泊苷和顺铂（MEC）治疗的尿路上皮移行细胞癌患者中的有效给药方法。重组人G-CSF在白细胞计数低于3000/mm³后开始皮下注射，剂量为2微克/千克（短期给药），或在MEC治疗结束后立即开始给药（预防性给药）。对照组、短期给药组和预防性给药组的白细胞最低值中位数分别为275±77、250±317和2066±47/mm³。对照组、短期给药组和预防性给药组白细胞计数低于1000/mm³的天数分别为6.6±0.6、4±2和0.9±0.5天。对照组和预防性给药组之间的差异具有统计学意义（p<0.01）。这些结果表明，MEC治疗后预防性给予rhG-CSF对预防白细胞减少有效。MEC治疗后使用rhG-CSF还可减少口腔炎、腹泻和肺炎等其他副作用。
